Physician profile
Thomas A Longo
NPI 1154559904
$2,667.19
in general payments reported to CMS, 2019-2025
16 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2021: $15.27 · 2022: $115 · 2023: $184 · 2024: $116 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,920.00 | 2019 | |
| Merck Sharp & Dohme LLC | $189.82 | 2023-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $114.65 | 2022 | |
| Coloplast Corp | $110.53 | 2019 | |
| Teleflex LLC | $71.86 | 2021-2025 | Urolift, Barrigel |
| Olympus America INC. | $43.72 | 2025 | Bovie, Itind System |
| Dendreon Pharmaceuticals LLC | $31.95 | 2024 | Provenge |
| Civco Medical Instruments | $30.44 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $27.74 | 2025 | Gemtesa |
| Pfizer INC. | $27.54 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.59 | 2025 | Lynparza |
| Sun Pharmaceutical Industries INC. | $18.01 | 2025 | |
| Halozyme INC | $17.17 | 2023 | |
| Blue Earth Diagnostics | $16.40 | 2024 | |
| Foundation Medicine, INC. | $14.96 | 2023 | Foundationone Liquid Cdx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $13.81 | 2023 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Longo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.